Abstract: Systems and methods are provided for sharing movie information online. In one implementation, the user of an online movie service can share information about the contents of a library or other such rights locker, e.g., under Ultraviolet™ and DECE. Users may also share likes and dislikes. The movie service may make suggestions based on the contents of the user's library and the contents of other user's libraries, such as those of the user's designated friends. A user can become a follower or fan of another user and receive recommendations based on the target user's profile or specific recommendations made by the target. The user can receive a credit on their account or on a related account when another user makes a purchase that is attributable to that user, e.g., from a recommendation. A user may be designated as an influencer when followed by a sufficient number of other users.

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

Abstract: The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

Abstract: A vehicle includes a first member and a second member moveable relative to the first member. A compliant member is compressible between the first member and the second member. A compression control device is attached to one of the first member and the second member for engaging another of the first member and the second member, or the compliant member. The compression control device is moveable between a first position and a second position. When disposed in the first position, the compression control device is not engaged with the first member, the second member, or the compliant member, and allows compression of the compliant member into a first compressive state. When disposed in the second position, the compression control device is engaged with one of the first member, the second member, or the compliant member, and is operable to compress the compliant member into a second compressive state.

Abstract: Storing, building, managing, and controlling consumer personal information, including: building at least one level of personal information according to a standard; storing the personal information on a consumer rights locker; defining a scope of access under terms of a consumer to control access to the consumer rights locker; transmitting a plurality of parameters needed to access the consumer rights locker; receiving a request to access the consumer rights locker and the plurality of parameters; comparing the plurality of parameters to the scope of access; and granting access to the consumer rights locker when it is determined that the request is valid, wherein the request is valid when the plurality of parameters includes an access right that is consistent with information in the scope of access. Keywords include consumer rights locker and personal information.

Abstract: Measures, including methods, systems and computer program products, for use in processing route data in a network comprising a plurality of autonomous systems. At a network device, route data defining at least one route for network traffic which is configured on at least one border network device is received from the at least one border network device. The at least one border network device is located at a border of an autonomous system in the plurality of autonomous systems. The network device processes the received route data according to a set of policies to generate modified route data. The network device transmits at least a part of the modified route data to the at least one border network device. The at least part of the modified route data is operable to instruct the at least one border network device to modify the behavior of the at least one route.

Abstract: Storing, building, managing, and controlling consumer personal information, including: building at least one level of personal information according to a standard; storing the personal information on a consumer rights locker; defining a scope of access under terms of a consumer to control access to the consumer rights locker; transmitting a plurality of parameters needed to access the consumer rights locker; receiving a request to access the consumer rights locker and the plurality of parameters; comparing the plurality of parameters to the scope of access; and granting access to the consumer rights locker when it is determined that the request is valid, wherein the request is valid when the plurality of parameters includes an access right that is consistent with information in the scope of access. Keywords include consumer rights locker and personal information.

Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

Abstract: The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: Apparatus and methods are provided to implement a technique for providing supplemental information and interactive features for content, such as a movie. In one implementation, a content provider builds a package of information and interactive features (“interactive extras”) using a defined structure and API (application programming interface). The content provider gives the package of extras to several distributors (or provides access to some or all of the package through a network resource). Each distributor uses the package in the distributor's content distribution platform or system by conforming to the API for the package. In this way, the content provider can provide the same package of extras to multiple distributors that may have incompatible platforms without having to build custom packages for each platform. This allows the content provider to build the package once and also provides a more consistent experience across the distributor services.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

Abstract: Managing and accessing media items, including: a plurality of domains configured to provide access to media items; a plurality of clients associated with the plurality domains, and providing a pathway for accessing the media items; and a spanning application configured to track and aggregate accessible media items from the plurality of domains based on authentication and registration information and associated rights of the plurality of clients and the plurality of domains, wherein the spanning application enables accessing of the media items across the plurality of domains.

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

Abstract: The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

Abstract: A dual-strake assembly can be coupled to the underbody of the vehicle in order to maximize the downforce-to-drag ratio, thereby enhancing the vehicle aerodynamic efficiency. The dual-strake assembly includes a first strake and a second strake having different curvatures. The second strake has a chord length. Each of the first and second strakes has a first edge and a second edge opposite the first edge. The first edges of the first and second strakes are spaced apart from each other so as to define a gap, which has a gap distance measured from the first edge of the first strake to the first edge of the second strake. The gap distance is equal to or less than twenty-five percent of the chord length. The camber of the first strake is less than the camber of the second strake.

Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.

Abstract: A dual-strake assembly can be coupled to the underbody of the vehicle in order to maximize the downforce-to-drag ratio, thereby enhancing the vehicle aerodynamic efficiency. The dual-strake assembly includes a first strake and a second strake having different curvatures. The second strake has a chord length. Each of the first and second strakes has a first edge and a second edge opposite the first edge. The first edges of the first and second strakes are spaced apart from each other so as to define a gap, which has a gap distance measured from the first edge of the first strake to the first edge of the second strake. The gap distance is equal to or less than twenty-five percent of the chord length. The camber of the first strake is less than the camber of the second strake.